Table 1.
Morphologic, immunophenotypic, cytogenetic and molecular data
| No | Morphology | Matutes score | CD38 | Treated before K | Time Diagnosis-K (months)* | Sample | Karyotype (according to ISCN2009) | IGHV mutation % identity | V rearrangement |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Atypical CLL | 3 | 95% | No | 98 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[13]/47,idem,?del(3)(p14p22),add(9)(q34),del(10)(q23),add(17)(q23)[6] | nd | nd |
| 2 | CLL | 4 | 1% | No | 4 | Pb | 46,XY,t(14;18)(q32;q21)[15]/46,XY[16] | nd | nd |
| 3 | CLL | 2 | 1% | No | 0 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[2]/46,XX[13] | nd | nd |
| 4 | CLL | nd | 2% | No | 80 | Pb | 46,XY,del(13)(q13q22),t(14;18)(q32;q21)[20] | nd | nd |
| 5 | CLL | 5 | 2% | No | 30 | Pb | 46,XY,t(14;18)(q32;q21)[9]/46,XY[5] | nd | nd |
| 6 | CLL¤ | 4 | 0% | No | 18 | Pb | 46,XY,t(14;18)(q32;q21)[16]/46,XY[3] | M | V3-23 |
| 7 | CLL | 4 | 5% | No | 5 | Pb | 46,XX,t(14;18)(q32;q21)[7]/46,idem,del(10)(q23q24)[7]/46,idem,der(1)t(1;1)(p12;q34),add(5)(p15),del(20)(q12)[7]/46,XX[4] | M | V3-23 |
| 8 | CLL | 4 | 0% | No | 0 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[10]/46,XY[13] | M | V4-4 |
| 9 | CLL | 5 | 26% | No | 39 | Pb | 46,XX,t(14;18)(q32;q21)[15]/47,idem, + 12[5] | nd | nd |
| 10 | CLL | 4 | 57% | No | 102 | Pb | 47,XY,?add(1)(p36), + 12,t(14;18)(q32;q21)[19]/46,XY[2] | nd | nd |
| 11 | CLL | 4 | nd | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[2]/46,XY[20] | nd | nd |
| 12 | Atypical CLL | 5 | 0% | No | 0 | Pb | 47,XY, + 12,?del(13)(q14q21)[2]/47,idem,t(14;18)(q32;q21)[7]/46,XY[10]** | nd | nd |
| 13 | Atypical CLL | 3 | Pos^ | No | 0 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[16]/46,XY[4] | M | V2-5 |
| 14 | CLL | 4 | Neg^ | No | 0 | Pb | 47,XY,+X,t(14;18)(q32;q21)[18]/47,idem,der(5)del(5)(p13p14)del(5)(q12q2?1),der(12)(12p13->p12::12q13->p11::12q14->q24::?)[4] | M | V3-9 |
| 15 | Atypical CLL | 4 | 10% | No | 0 | Bm | 47,XY,+X,t(14;18)(q32;q21)[16]/46,XY[4] | nd | nd |
| 16 | Atypical CLL | 5 | Neg^ | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[16]/46,idem,?del(13)(q14q24)[2]/46,XY[14]** | nd | nd |
| 17 | Atypical CLL | 5 | nd | Yes | 165 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[11]/46,XY[9] | nd | nd |
| 18 | Atypical CLL | 4 | Neg^ | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[2]/46,XY[18] | nd | nd |
| 19 | Atypical CLL | 4 | Neg^ | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[3]/46,XY[18] | nd | nd |
| 20 | CLL¤ | nd | nd | Un | 40 | Pb | 47,XY, + 12,t(18;22)(q21;q11)[19]/46,XY[1] | nd | nd |
| 21 | CLL¤ | nd | nd | No | 36 | Pb | 46,XY,t(18;22)(q21;q11)[17]/46,XY[3] | nd | nd |
| 22 | Atypical CLL | 5 | 2% | No | 90 | Pb | 46,XY,t(14;18)(q32;q21)[17]/46,idem,del(13)(q14q21)[3]/46,XY[2] | M | V3-33 |
| 23 | CLL¤ | 4 | 11% | No | 78 | Pb | 46,XY,t(14;18)(q32;q21)[4]/46,idem,t(13;22)(q14;p11)[9]/46,XY[9] | nd | nd |
| 24 | CLL¤ | 4 | 65% | Yes | 28 | Pb | 46,XX,t(1;14)(q31;q32),t(2;14)(p12;q32),t(18;22)(q21;q11)[20] | NM | V3-30 |
| 25 | Atypical CLL | 4 | 7% | Yes | 188 | Pb | 46,XY,t(14;18)(q32;q21)[2]/46,idem,del(5)(q13q31),inv(12)(q13q24)[11]/46,idem,add(4)(p11),add(10)(q22),-11,+mar[8]/46,XY[1] | M | V2-5 |
| 26 | CLL¤ | nd | 95% | Yes | 211 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[2]/47,XX,+X[2]/46,XX[39] | M | V5-51 |
| 27 | Atypical CLL | nd | 92% | No | 6 | Pb | 46,XX,t(14;18)(q32;q21)[1]/47,idem, + 12[1]/46,XX[40] | M | V3-74 |
| 28 | CLL | 3 | 0% | No | 15 | Pb | 46,XY,t(14;18)(q32;q21)[3]/46,XY[14]/47,idem,+X[5]/46,XY[1] | M | V3-23 |
| 29 | CLL¤ | 2 | 9% | No | 0 | Bm | 46,XX,t(14;18)(q32;q21)[5]/6,XX[16] | M | V1-69 |
| 30 | CLL¤ | 4 | 84% | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[10]/46,idem,r(7)(?)[4]/47,idem, + 12[2]/46,XY[1] | NM | V1-69 |
| 31 | Atypical CLL | 4 | 95% | No | 0 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[19]/46,XY[6] | nd | nd |
| 32 | Atypical CLL | 5 | 6% | No | 0 | Bm | 46,XY,t(14;18)(q32;q21)[11]/46,XY[9] | nd | nd |
| 33 | CLL | 4 | 3% | No | 19 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[20] | nd | nd |
| 34 | CLL¤ | 4 | 8% | Yes | 12 | Pb | 46,XY,t(14;18)(q32;q21)[20] | nd | nd |
| 35 | CLL¤ | 5 | 0% | Yes | 69 | Pb | 46,XY,t(6;17)(p21;p13),t(14;18)(q32;q21)[20] | nd | nd |
| 36 | CLL¤ | 4 | nd | No | 17 | Pb | 46,XY,del(13)(q13q22),t(14;18)(q32;q21)[17]/46,XY[3] | nd | nd |
| 37 | CLL | 4 | 7% | No | 7 | Pb | 45,XY,der(1)t(1;8)(q41;q13),del(7)(p15p22),-8,t(18;22)(q21;q11)[20] | nd | nd |
| 38 | CLL | 5 | 7% | No | 40 | Pb | 46,XX,t(14;18)(q32;q21)[11]/46,XX[16] | M | V5-51 |
| 39 | CLL | 4 | nd | No | 46 | Pb | 46,XY,t(18;22)(q21;q11)[19]/46,XY[2] | M | V4-39 |
| 40 | CLL | 4 | 3% | No | 41 | Pb | 46,XY,t(14;18)(q32;q21)[4]/46,XY[13] | M | V4-34 |
| 41 | CLL | 4 | 5% | No | 4 | Pb | 46,XY,t(2;18)(p11;q21)[9]/46,XY[2] | M | V3-9 |
| 42 | CLL | 5 | nd | No | 56 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[13]/46,XX[1] | M | V3-30 |
| 43 | CLL | 2 | 90% | No | 26 | Pb | 46,XY,t(14;18)(q32;q21)[6]/46,XY[11]£ | nd | nd |
| 44 | Atypical CLL | 5 | nd | No | 47 | Pb | 47,XY, + 12[21]/47,idem,t(14;18)(q32;q21)[4] | NM | V3-7 |
| 45 | Atypical CLL | 4 | 3% | No | 5 | Pb | 47,XY, + 12,t(18;22)(q21;q11)[16]/46,XY[1] | NM | V2-70 |
| 46 | CLL | 5 | 0% | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[17]/46,idem,del(13)(q14q24)[2] | nd | nd |
| 47 | CLL | 4 | 7% | No | 0 | Bm | 46,XY,t(14;18)(q32;q21)[9]/46,XY[1] | M | V3-48 |
| 48 | CLL | 5 | 13% | No | 88 | Pb | 46,XY,t(14;18)(q32;q21)[7]/46,XY[3] | M | V5-51 |
| 49 | CLL | 4 | 0% | No | 81 | Pb | 46,XX,-4,add(8p)(p21),der(14)del(14)(q21q24)t(14;18)(q32;q21),der(18)t(14;18),+mar[10] | M | V3-48 |
| 50 | Atypical CLL | 5 | 1% | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[17]/46,XY[3] | M | V3-23 |
| 51 | CLL | 5 | 1% | Un | 27 | Pb | 46,XY,del(13)(q14q2?1),t(18;22)(q21;q11)[12]/46,XY[3] | M | V4-34 |
| 52 | Atypical CLL | 5 | 4% | Yes | 145 | Pb | 46,XY,t(14;18)(q32;q21)[11]/46,idem,del(13)(q14q3?1)[6]/46,XY[2] | M | V3-07 |
| 53 | Atypical CLL | 4 | 61% | No | 5 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[7]/46,XX[13] | NM | V6-1 |
| 54 | CLL¤ | 5 | 61% | Un | 32 | Pb | 47,XY, + 12[18]/47,idem,t(18;22)(q21;q11)[2] | NM | V1-69 |
| 55 | Atypical CLL | 5 | 4% | No | 1 | Pb | 47,XY, + 12[2]/47,idem,t(14;18)(q32;q21)[14]/46,XY[5] | nd | nd |
| 56 | Atypical CLL | 4 | 47% | No | 31 | Pb | 46,XX,t(18;22)(q21;q11)[8]/46,idem,t(4;20)(q13;q11)[16]/47,idem, + 12[2] | M | V3-7 |
| 57 | Atypical CLL | 3 | nd | No | 6 | Pb | 46,XY,t(14;18)(q32;q21)[10]/46,XY[10] | M | V3-30 |
| 58 | CLL | 5 | 1% | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[2]/46,XY[18] | M | V3-74 |
| 59 | Atypical CLL | 5 | 70% | No | 6 | Pb | 46,XY,t(14;18)(q32;q21)[2]/46,XY[18] | M | V3-23 |
| 60 | Atypical CLL | 3 | nd | No | 16 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[2]/46,XX[18] | M | V4-34 |
| 61 | Atypical CLL | 4 | 20% | Yes | 22 | Pb | 47,XX, + 12[15]/47,idem,t(14;18)(q32;q21)[6]/46,XX[1] | NM | V1-69 |
| 62 | CLL¤ | 5 | 59% | No | 34 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[2]/46,XY[18] | NM | V3-11 |
| 63 | Atypical | nd | nd | No | 26 | Pb | 47,XY,add(4)(q?34), + 12,t(14;18)(q32;q21)[16]/46,XY[4] | nd | nd |
| 64 | Atypical CLL | nd | 3% | Un | Un | Pb | 46,XY,t(2;18)(p11;q21)[8]/49,idem,+6, + 12,+21[3]/46,XY[9] | nd | nd |
| 65 | Atypical CLL | 5 | 0% | No | 0 | Pb | 46,XY,t(14;18)(q32;q21)[6]/46,XY[24] | M | V3-53 |
| 66 | CLL¤ | 4 | 2% | No | 84 | Pb | 46,XY,t(18;22)(q21;q11)[27]/46,XY[3] | nd | nd |
| 67 | CLL | 4 | 0% | No | 98 | Pb | 46,XY,t(14;18)(q32;q21)[20] | M | V3-23 |
| 68 | CLL | 5 | 0% | No | 26 | Pb | 46,XY,t(14;18)(q32;q21)[18]/46,XY[2] | nd | nd |
| 69 | CLL | 4 | 1% | No | 0 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[11]/47,idem,del(13)(q11)[2]/46,XX[7] | nd | nd |
| 70 | CLL | 3 | 79% | No | 12 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[8] | M | V3-7 |
| 71 | CLL¤ | 4 | 3% | No | 1 | Pb | 46,XY,t(14;18)(q32;q21)[10] | nd | nd |
| 72 | CLL¤ | 5 | 4% | No | 29 | Pb | 46,XY,t(14;18)(q32;q21)[5]/47,idem, + 12[7] | nd | nd |
| 73 | Atypical CLL | 2 | 85% | No | 0 | Pb | Failure££ | M | V3-48 |
| 74 | CLL¤ | 3 | 59% | No | 188 | Pb | 47,XY,+12,del(13)(q13q21),t(18;22)(q21;q11)[5]/47,idem,del(10)(q24)[6]/47,idem,t(3;12)(p21;q24)[5]/47,idem,t(2;11)(q22;q22)[4] | M | V4-34 |
| 75 | CLL¤ | 4 | 8% | No | 10 | Pb | 46,XX,t(14;18)(q32;q21)[5]/46,idem,del(13)(q13q22)[3]/46,XX[10] | M | V1-69 |
| 76 | MZL | 1 | 99% | No | 0 | Pb | 47,XX, + 12,t(14;18)(q32;q21)[12]/46,XX[8] | M | V3-23 |
| 77 | MZL | 3 | 38% | No | 4 | Pb | 47,XY,t(2;18)(p11;q21), + 12[11]/46,XY[9] | nd | nd |
| 78 | MZL | 1 | 1% | No | 0 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[5]/46,XY[15] | nd | nd |
| 79 | MZL | 2 | 95% | No | 0 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[12]/46,XY[7] | M | V3-23 |
| 80 | MZL | 0 | 83% | No | 33 | Pb | 47,XY, + 12,t(14;18)(q32;q21)[18]/46,XY[1] | nd | nd |
CLL: chronic lymphocytic leukemia. MZL: marginal zone lymphoma.
¤
not rewieved. nd: not done. Un: unknown.
^
% not communicated, the cut off being 20%.of cells. Bm: bone marrow. Pb: peripheral blood. K:karyotype. NM : unmutated, M: mutated.
*
time between Diagnosis and Karyotype.
£
: Using FISH, trisomy 12 was detected in a sub-clone.
££
Using FISH, trisomy 12 was present.
**
No 13q14 deletion was detected using FISH.